|Bid||1.9700 x 900|
|Ask||1.9900 x 900|
|Day's Range||1.8200 - 1.9900|
|52 Week Range||1.8000 - 7.6900|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
A look at the shareholders of Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Wells Fargo Securities 2018 Healthcare Conference on Thursday, September 6, 2018 at 10:20 A.M. Eastern Time at the Westin Copley Place in Boston, MA. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia.
The South San Francisco, California-based company said it had a loss of 20 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $2.45. A year ago, they were trading at ...
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018-- Sunesis Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2018. Loss from operations for the three and six months ended ...
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Tuesday, August 7th, 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2018. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for one year.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced three key new management appointments as part of the Company’s expansion of its development team. Deepali Suri, M.Sc., a former Executive Director at Pharmacyclics (an AbbVie Company), was appointed Vice President, Clinical Operations, and Sean Gharpurey, M.S., MBA, joined as Executive Director, Project Management. Stephen Nava was promoted to Vice President, Quality Assurance, Compliance and Regulatory Affairs.
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it has entered into a Common Shares Purchase Agreement (the “Agreement”) of up to $15.5 million with Aspire Capital Fund, LLC (“Aspire Capital”). Under the terms of the Agreement, Aspire Capital has made an initial investment via purchase of $500,000 worth of SNSS common shares at a price of $2.19 per common share. In addition, Aspire Capital has committed to purchasing up to an additional $15 million of common shares of Sunesis, at Sunesis’ request from time to time during a 24-month period beginning on the effective date of a registration statement related to the transaction and at prices based on the market price at the time of each sale.
The South San Francisco, California-based company said it had a loss of 21 cents per share. The biopharmaceutical company posted revenue of $237,000 in the period. In the final minutes of trading on Tuesday, ...
Investors in Sunesis Pharmaceuticals (SNSS) need to pay close attention to the stock based on moves in the options market lately.
The South San Francisco, California-based company said it had a loss of 21 cents per share. For the year, the company reported that its loss narrowed to $35.5 million, or $1.45 per share. Revenue was reported ...
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:30 PM Eastern ...
On Thursday, Sunesis Pharmaceuticals (NASDAQ: SNSS ) will report its last quarter's earnings. Here is Benzinga's take on the company's release. Earnings and Revenue Sunesis Pharmaceuticals EPS loss will ...
Measuring Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations,Read More...